Sponsors
Introduced March 3, 2025 by Frank Pallone · Last progress March 3, 2025
The bill increases transparency, access to care, public‑health preparedness, and some consumer protections, but does so through large new spending and extensive reporting rules that will raise compliance costs, create privacy and administrative burdens, and could disrupt smaller providers and businesses.
Most patients and health-plan enrollees will gain much greater transparency into drug prices, PBM payments, rebates, and net costs, enabling employers, plans, and consumers to compare prices and potentially negotiate or seek lower-cost options.
Medicaid, Medicare, and other beneficiaries (including children, seniors, and people with disabilities) will see expanded and preserved access to care — faster out‑of‑state provider enrollment, extended telehealth protections, hospital‑at‑home and home infusion coverage, and more HCBS planning funds — improving continuity and options for care.
The bill strengthens public‑health and pandemic preparedness — increasing funding and coordination for vaccines, BARDA/biomedical surge capacity, stockpiles, diagnostics, antimicrobial-resistance efforts, workforce training, and CBRN countermeasure planning — improving national readiness for future threats.
Taxpayers could face substantially higher federal spending and potential deficits (multi‑hundred‑million to multi‑billion authorizations and new appropriations across health, preparedness, and other programs), which may require offsets or future tax/benefit tradeoffs.
Extensive new reporting, disclosure, and audit requirements for PBMs, plans, pharmacies, manufacturers, and providers impose heavy compliance and IT costs that are likely to be passed on to employers, plan sponsors, or enrollees through higher premiums or administrative fees.
States, providers, and federal agencies face substantial new administrative burdens (system upgrades, reporting, attestations, inventory/studies, and rulemaking deadlines) that will require staffing and IT expenditures and could slow or complicate program rollouts.
Based on analysis of 37 sections of legislative text.
Imposes detailed PBM and plan transparency/reporting, changes Medicare/Medicaid coverage and reporting rules, updates consumer safety standards, funds manufacturing/tech initiatives, and directs multiple studies and agency actions.
This bill creates a wide package of actions to lower costs and increase transparency across health care, public health, manufacturing, technology, and consumer safety. Major health provisions force pharmacy benefit managers (PBMs) and group health plans to provide detailed, machine-readable reports on drug costs, rebates, and pharmacy payments, expand certain Medicare coverage rules (telehealth billing tags, home infusion pump access, hospital-at-home evaluation), change Medicaid enrollment and home‑and‑community‑based services reporting, and limit certain patent assertions in biosimilar litigation. It also directs federal agencies to expand domestic manufacturing and supply-chain programs, authorizes technology and standards work (including blockchain advisory roles and NTIA reauthorization), requires product safety actions (a ban on certain consumer sodium nitrite products and adoption of lithium‑ion battery standards), funds public-health preparedness and countermeasures, commissions multiple studies (GAO, MedPAC), and creates civil penalties and compliance timelines for new reporting rules. Effective dates vary by provision (many health reporting rules begin 30 months after enactment; some items have shorter timelines like a 90‑day ban effective for certain consumer products).